RecruitingNot Applicable

HRQoL and Financial Toxicity in Patients With VEXAS Syndrome

Italy100 participantsStarted 2024-11-01

Plain-language summary

This multicenter cross-sectional observational study aims to describe health-related quality of life (HRQoL) and symptom profiles of patients with VEXAS syndrome.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients (≥ 18 years old) with a confirmed diagnosis of VEXAS syndrome (UBA1 pathogenic mutation detected) * Written informed consent Exclusion Criteria: * \- Having any kind of psychiatric disorder or major cognitive dysfunction. * Not able to read and understand local language

What they're measuring

EORTC QLQ-C30

Timeframe: one time at study entry

FACIT-Fatigue

Timeframe: one time at study entry

Trial details

NCT IDNCT06657846

SponsorGruppo Italiano Malattie EMatologiche dell'Adulto

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-10

Contact for this trial

Fabio Efficace

+39 06 441639831 f.efficace@gimema.it

View on ClinicalTrials.gov More VEXAS trials